Oct 12, 2021 / 06:30PM GMT
Ed Arce - H.C. Wainwright & Co. - Analyst
Hello, and welcome to the H.C. Wainwright fifth annual NASH investor conference. My name is Ed Arce. I'm one of the senior biotech analysts here at H.C. Wainwright. And I am now very pleased to introduce our next presenting company, DURECT. And representing the Company is Jim Brown, the President and CEO; Mike Arenberg, the Chief Financial Officer; Dr. WeiQi Lin, the Executive Vice President of R&D and Principal Scientist; and last but not least, Dr. Norman Sussman, the Chief Medical Officer. Welcome, everyone.
Norman Sussman - DURECT Corporation - Chief Medical Officer
Hello, Ed.
Jim Brown - DURECT Corporation - President & CEO
Thank you, Ed. Thanks for having us here today.
Questions and Answers:
Ed Arce - H.C. Wainwright & Co. - AnalystAbsolutely. Glad you could join us. So let's jump right in. Of course, those that have been following your story more recently would know that DUR-928 is your lead compound.
Trustpilot
